Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas.
The advance of monoclonal antibody (MoAb) technology in recent years provides a further treatment modality for cancer therapy. In this review, we discussed the various strategies available for MoAb therapy. We also addressed the problems encountered so far in early clinical trials and suggested possible solutions. We finally reviewed some of the interesting clinical studies conducted so far on the use of MoAbs in patients with non-Hodgkin's lymphomas.
Lim
S H
SH
Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Marcus
R E
RE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D016026:Bone Marrow Transplantation; D005069:Evaluation Studies as Topic; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage / Q000627:therapeutic use; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D016499:Radioimmunotherapy; D012276:Ricin / Q000008:administration & dosage / Q000627:therapeutic use; D016879:Salvage Therapy; D014182:Transplantation, Autologous
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000922:Immunotoxins; D007457:Iodine Radioisotopes; D012276:Ricin